Carlsen N L, Hesselbjerg U, Glenting P
J Antimicrob Chemother. 1985 Oct;16(4):509-17. doi: 10.1093/jac/16.4.509.
Thirty-five children with a history of vesicoureteric reflux or with recurrent urinary tract infections were randomly allocated to low-dose prophylactic treatment with pivmecillinam or nitrofurantoin. After 6-10 months they were crossed over to the alternate drug for another 6 months, but only 24 completed the study because of lack of compliance or intolerance to nitrofurantoin. There was no significant difference in the long-term prophylactic effect between the two drugs, the overall infection rate being 0.7/patient-year. Pivmecillinam was significantly better tolerated than nitrofurantoin (P = 0.01). Nitrofurantoin effected no major change in the faecal flora, and nearly all urinary infections occurring during long-term treatment were caused by Escherichia coli. In contrast, a marked reduction of E. coli and a marked increase in Gram-positive cocci were found in the faecal flora during treatment with pivmecillinam. Seventy per cent of infections were caused by Streptococcus faecalis and only 20% by E. coli during pivmecillinam treatment (P = 0.001).
35名有膀胱输尿管反流病史或复发性尿路感染的儿童被随机分配接受低剂量的匹美西林或呋喃妥因预防性治疗。6至10个月后,他们换用另一种药物再治疗6个月,但由于对呋喃妥因不耐受或依从性差,只有24名儿童完成了研究。两种药物的长期预防效果无显著差异,总体感染率为0.7/患者年。匹美西林的耐受性明显优于呋喃妥因(P = 0.01)。呋喃妥因对粪便菌群无重大影响,长期治疗期间几乎所有尿路感染均由大肠杆菌引起。相比之下,在使用匹美西林治疗期间,粪便菌群中大肠杆菌显著减少,革兰氏阳性球菌显著增加。在匹美西林治疗期间,70%的感染由粪肠球菌引起,仅20%由大肠杆菌引起(P = 0.001)。